Gene · 57674
Papers1,364
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,364
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and genotype-phenotype correlation of RNF213 p.R4810K and non- p.R4810K variants in Moyamoya disease in an Indian cohort. | Front Neurol | 2026 | 42824198 | PubTator, text mining | PubMed |
| ZNFX1, an immunoregulatory RNA helicase and E3 ubiquitin ligase, assembles into pleiomorphic polymers. | Mol Cell | 2026 | 42822417 | PubTator, text mining | PubMed |
| Toxoplasma gondii GRA66 prevents premature egress driven by the host phospholipase RARRES3, independently of RNF213. | bioRxiv | 2026 | 42818749 | PubTator, text mining | PubMed |
| RNF213 regulates palmitate signaling through AAA+ and RZ-finger domains, a process enhanced by gain-of-function moyamoya disease-associated mutations. | FEBS J | 2026 | 42681960 | PubTator, text mining | PubMed |
| Plasma signatures of type 2 inflammation and vascular remodeling in moyamoya disease. | J Neurol Sci | 2026 | 42664850 | PubTator, text mining | PubMed |
| RNF213-dependent lytic destruction of Chlamydia-containing vacuoles activates host cell death pathways. | Proc Natl Acad Sci U S A | 2026 | 42658761 | PubTator, text mining | PubMed |
| Pulmonary Arterial Hypertension With Moyamoya Disease Harboring the RNF213 p.Arg4810Lys Variant Presenting a Favorable Response to Monotherapy: A Case Report. | Pulm Circ | 2026 | 42657248 | PubTator, text mining | PubMed |
| RNF213 in Panvascular Disease: A Molecular Hub Linking Genetic Susceptibility to Systemic Vasculopathy. | Biomedicines | 2026 | 42652131 | PubTator, text mining | PubMed |
| Independent Association of RNF213 p.R4810K With Extracranial Carotid Artery Disease Beyond Intracranial Atherosclerosis. | Stroke | 2026 | 42644243 | PubTator, text mining | PubMed |
| Pediatric moyamoya: current evidence and updates in evaluation and management. | Curr Opin Pediatr | 2026 | 42627237 | PubTator, text mining | PubMed |
| RNF213-related vasculopathy: beyond a linear "pre-moyamoya" model. | Lancet Reg Health West Pac | 2026 | 42621208 | PubTator, text mining | PubMed |
| RNF213-related vasculopathy beyond a linear pre-moyamoya model: authors' reply. | Lancet Reg Health West Pac | 2026 | 42602922 | PubTator, text mining | PubMed |
| Spatial decoupling of plaque and circulating immune programs defines a robust gene signature in atherosclerosis: A multi-cohort integrative analysis. | Medicine (Baltimore) | 2026 | 42601724 | PubTator, text mining | PubMed |
| The Impact of VEGFA rs2010963 on Bilaterality and Posterior Artery Stenosis in Patients with Moyamoya Disease. | Transl Stroke Res | 2026 | 42554913 | PubTator, text mining | PubMed |
| A Phenotype-Based Score to Prioritize RNF213 p.R4810K Genotyping in Isolated Intracranial Steno-Occlusive Disease. | Transl Stroke Res | 2026 | 42541694 | PubTator, text mining | PubMed |
| RNF213 marks a regulatory T-cell subset associated with ulcerative colitis. | Front Immunol | 2026 | 42519321 | PubTator, text mining | PubMed |
| Collateral circulation after revascularization in moyamoya disease: influencing factors and underlying mechanisms. | Front Neurol | 2026 | 42518953 | PubTator, text mining | PubMed |
| Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy. | J Immunother Cancer | 2026 | 42419880 | PubTator, text mining | PubMed |
| Molecular Glues Recruiting RNF213 As an E3 Ligase for Targeted Protein Degradation: A Minimal Dibromoacetamide Warhead As a Recruitment Ligand. | J Am Chem Soc | 2026 | 42336393 | PubTator, text mining | PubMed |
| Host Genetic Regulation of NLRP3 Inflammasome Cytokines Reveals Immune and Vascular Pathways in HIV. | medRxiv | 2026 | 42326826 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57674/papers